Stephen Lane, MD, shared full results from the post-approval COMPASS-XT study at the 2018 ESCRS meeting in Lisbon, Portugal. The long-term safety data offers new insights into Alcon’s decision to withdraw the CyPass microstent from global markets last month. Source: AAO
This paper reports results from a phase 2 trial evaluating oral valproic acid for treating autosomal dominant retinitis pigmentosa. Source: AAO
This large retrospective analysis compared the rotational stability of the Acrysoft and Tecnis toric IOLs. Source: AAO
This study assessed the diagnostic accuracy of 3D high-resolution T1-weighted black-blood magnetic resonance imaging (T1-BB-MRI) for the detection of posterior ciliary artery involvement in patients with giant cell arteritis and funduscopic arteritic anterior ischemic optic neuropathy (A-AION). Source: AAO
The FDA awarded fast track designation to a single-administration, intravitreal gene therapy for wet AMD, according to a press release by Adverum Biotechnologies. Source: AAO
This observational study estimated annual Medicare Part B spending on 2 anti-VEGF drugs. Source: AAO
This study reports the outcomes of silicone Ahmed glaucoma valve (AGV) implantation in the management of refractory pediatric glaucoma. Source: AAO
This week, the ASCRS assesses implications of the Cypass microstent withdrawal, Today show co-anchor Craig Melvin describes his corneal ulcer diagnosis and an experimental gene therapy for X-linked retinitis pigmentosa begins trials in the United States. Source: AAO
Regulatory officials have approved Xelpros 0.005%, a first-line treatment for open-angle glaucoma and ocular hypertension that lacks the preservative benzalkonium chloride. Source: AAO
In this retrospective analysis, the authors examined corneal transplant survival rates based on patients’ primary corneal diagnosis and type of regraft surgery. Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »
